ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Review |
Article Title |
Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of in vivo studies
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Zaid Al-Dhamin, Ling-Di Liu, Dong-Dong Li, Si-Yu Zhang, Shi-Ming Dong and Yue-Min Nan |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Key Research and Development Program of Hebei Province |
19277779D |
The Program of Introduce International Intelligence of Hebei Province |
|
|
Corresponding Author |
Yue-Min Nan, MD, PhD, Director, Director, Doctor, Doctor, Professor, Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University & Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, No. 139 Ziqiang Road, Shijiazhuang 050051, Hebei Province, China. nanyuemin@163.com |
Key Words |
Bone marrow; Mesenchymal stem cells; Liver fibrosis; In vivo; Efficiency; |
Core Tip |
Bone marrow (BM)-derived mesenchymal stem cells (MSCs) are a promising therapy for liver fibrosis. However, several aspects of this treatment are vague, such as efficiency. This review summarizes the recent advances and studies the effectiveness of BM-MSC therapy, its mechanisms and related factors, focusing on the preclinical in vivo experiments. While BM-MSCs appear to be effective in some cases, in others, the cotreatment appears to be the better option. Studies on strategies, implementation routes, and cotreatments are helping to strengthen the therapy's efficiency. While the potential of this therapy continues to advance, research is still needed to achieve full potential. |
Publish Date |
2020-12-19 11:55 |
Citation |
Al-Dhamin Z, Liu LD, Li DD, Zhang SY, Dong SM, Nan YM. Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of in vivo studies. World J Gastroenterol 2020; 26(47): 7444-7469 |
URL |
https://www.wjgnet.com/1007-9327/full/v26/i47/7444.htm |
DOI |
https://dx.doi.org/10.3748/wjg.v26.i47.7444 |